
    
      The protocol is a prospective, randomized, double-blinded, crossover study with Major
      Depressive Disorder (MDD) receiving bupropion HCl 300mg XL (branded or generic).

      Subjects will be studied in 4 phases for a total of approximately 28 weeks:

      Phase 1: an approximately 4-week lead-in phase during which participants remain on their
      existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6
      weeks on each of the four bupropion study drugs (brand and 3 generics).
    
  